ES2100148T3 - Aplicaciones terapeuticas de los agonistas beta-adrenergicos. - Google Patents

Aplicaciones terapeuticas de los agonistas beta-adrenergicos.

Info

Publication number
ES2100148T3
ES2100148T3 ES88308402T ES88308402T ES2100148T3 ES 2100148 T3 ES2100148 T3 ES 2100148T3 ES 88308402 T ES88308402 T ES 88308402T ES 88308402 T ES88308402 T ES 88308402T ES 2100148 T3 ES2100148 T3 ES 2100148T3
Authority
ES
Spain
Prior art keywords
beta
effects
adrenergic
adrenergic agonists
reversing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88308402T
Other languages
English (en)
Inventor
Charlotte Anne Maltin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rowett Research Institute
Original Assignee
Rowett Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878721602A external-priority patent/GB8721602D0/en
Priority claimed from GB888803619A external-priority patent/GB8803619D0/en
Application filed by Rowett Research Institute filed Critical Rowett Research Institute
Application granted granted Critical
Publication of ES2100148T3 publication Critical patent/ES2100148T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A NUEVOS EMPLEOS TERAPEUTICOS DE AGONISTAS BETA - ADRENERGICOS EN HOMBRES Y ANIMALES. LAS APLICACIONES INCLUYEN AUMENTAR EL CRECIMIENTO MUSCULAR Y REDUCIR LA ABSORCION DE GRASA DE LA INGESTA, RETARDAR O INVERTIR LA ATROFIA DE MUSCULOS DESNERVADOS, ALIVIAR O INVERTIR LOS EFECTOS DE VARIAS ENFERMEDADES (INCLUYENDO EL CANCER), MODIFICACION DEL CRECIMIENTO FETAL Y NEONATAL Y MODIFICACIONES GENETICAS DEL FETO EN DESARROLLO. ES AGONISTA BETA - ADRENERGICO PREFERIDO ES EL CLENBUTEROL. SORPRENDENTEMENTE EL AGONISTA BETA - ADRENERGICO SE PUEDE MEZCLAR CON UN ANTAGONISTA BETA - ADRENERGICO PARA OBVIAR O MITIGAR LOS EFECTOS SECUNDARIOS INDESEADOS, SIN INHIBIR EXCESIVAMENTE LOS EFECTOS NUEVOS DESEABLES.
ES88308402T 1987-09-15 1988-09-12 Aplicaciones terapeuticas de los agonistas beta-adrenergicos. Expired - Lifetime ES2100148T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878721602A GB8721602D0 (en) 1987-09-15 1987-09-15 Therapeutic applications of beta-adrenergic agonists
GB888803619A GB8803619D0 (en) 1988-02-17 1988-02-17 Therapeutic applications of beta-adrenergic agonists

Publications (1)

Publication Number Publication Date
ES2100148T3 true ES2100148T3 (es) 1997-06-16

Family

ID=26292734

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88308402T Expired - Lifetime ES2100148T3 (es) 1987-09-15 1988-09-12 Aplicaciones terapeuticas de los agonistas beta-adrenergicos.

Country Status (4)

Country Link
EP (2) EP0308157B1 (es)
AT (1) ATE149089T1 (es)
DE (1) DE3855801T2 (es)
ES (1) ES2100148T3 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU203040B (en) * 1988-07-05 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing weight-increasing composition containing 1-(3,5-dihydroxy-phenyl)-2-(terc-butyl-amino)-ethanol
US5281623A (en) * 1990-08-27 1994-01-25 Eli Lilly And Company Method for treating inflammation
EP0488435A1 (en) * 1990-11-26 1992-06-03 Duphar International Research B.V Method of increasing the muscle/fat ratio in agricultural domestic animals
US6524532B1 (en) 1995-06-20 2003-02-25 The Regents Of The University Of California Microfabricated sleeve devices for chemical reactions
US6015837A (en) * 1996-08-29 2000-01-18 New York Medical College Method for treating scoliosis with β2-adrenoceptor agonists
CA2455248A1 (en) * 2004-01-29 2005-07-29 Alexander Zolotoy Oral administration of r-albuterol against obesity
JP2009526087A (ja) 2005-12-22 2009-07-16 アナボレックス， インコーポレイテッド 悪液質の予防および処置のための組成物および方法
GB0625270D0 (en) * 2006-12-19 2007-01-31 Univ Leicester Angiogenesis
AU2008240379B2 (en) 2007-04-24 2012-10-04 Acacia Pharma Limited Drug combination of beta 2 agonist and a progestin for the treatment of muscle loss
PL220308B1 (pl) 2011-06-03 2015-10-30 Kobel Buys Krystyna Zastosowanie klenbuterolu do leczenia objawów autyzmu dziecięcego oraz klenbuterol do zastosowania w leczeniu objawów autyzmu dziecięcego
JO3192B1 (ar) * 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
IT202300021417A1 (it) 2023-10-13 2025-04-13 Univ Pisa Agonisti o attivatori del recettore adrenergico beta-3

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL60530A (en) * 1979-08-16 1984-10-31 American Cyanamid Co Animal feed compositions useful as growth promotors and for reduction of fat in animals,comprising phenylethanolamine derivatives and certain such novel compounds
IL70813A (en) * 1983-01-31 1987-10-30 Lilly Co Eli Animal feed comprising certain phenethanolamine derivatives and 1-phenyl-2-(1-methyl-3-(4-nitrophenyl)propylamino)ethanol hydrochloride
GB8806471D0 (en) * 1988-03-18 1988-04-20 Tisdale M J Biologically active material characterised by catabolic activity generally associated with cachexia inducing tumours

Also Published As

Publication number Publication date
EP0308157A2 (en) 1989-03-22
EP0662324A1 (en) 1995-07-12
EP0308157A3 (en) 1992-01-15
ATE149089T1 (de) 1997-03-15
DE3855801T2 (de) 1997-07-03
DE3855801D1 (de) 1997-04-03
EP0308157B1 (en) 1997-02-26

Similar Documents

Publication Publication Date Title
ES2100148T3 (es) Aplicaciones terapeuticas de los agonistas beta-adrenergicos.
IT1157365B (it) Medicamenti per trattare l'obesita' o ridurre il peso del corpo
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
EP0401903A3 (en) The use of vanilloids for the treatment of respiratory diseases or disorders
IL68350A (en) N-glycosylated carboxamide derivatives,their preparation and their use for the treatment of animals
ZA898605B (en) Compositions for topical treatment of skin diseases
IL83775A0 (en) Fumaramide derivatives and pharmaceutical compositions containing them for treating skin diseases
FR2651435B1 (es)
DE3889974D1 (de) Pyrazol-Derivate und diese enthaltende Behandlungsmittel für cerebrovaskulare Krankheiten.
GR3024763T3 (en) Use of human interferon-beta for stimulation of erythropoieses
EP0295559A3 (en) Pharmaceutical composition for the treatment of tumors
FR2600256B1 (fr) Medicament et composition medicamenteuse pour le traitement des tumeurs ainsi que pour le traitement des maladies infectieuses dues aux virus
ZA822158B (es)
ZA873928B (en) Topical methotrexate preparation for the treatment of hyperproliferative epithelial disease
FR2399406A1 (fr) Derives de perhydronaphtalenepentol et leur utilisation therapeutique
FR2419291A1 (fr) 2,3-dihydroimidazo(1,2-c)pyrimidines substituees et leur utilisation therapeutique
KR890017363A (ko) 스트로빌루린 유도체, 이들의 제법 및 용도
DE3374066D1 (en) N-acyl derivatives of peptides, their manufacture and use in combating diseases and means therefor
DE69011272D1 (de) 3-Substituierte-2-Oxindolderivate als Interleukin-Biosynthesehemmer.
ATE197764T1 (de) Zusammensetzung zur behandlung des insulinmangels bei säugetieren, die amylin und insulin enthält.
MY131097A (en) Pharmaceutical compositions comprising interleukin-2
BE885851A (fr) Composition therapeutique pour le traitement de la dustrophie musculaire, de la myopathie et de la myotonie
IL86731A (en) Pharmaceutical compositions containing estradien-3-one derivatives and androst-2-ene-carbonitrile derivatives
SU1797195A1 (ru) Способ профилактики радиационных поражений
Bernstein The case for lobotomy.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 308157

Country of ref document: ES